Prior to his current role at DGHI, Jeff Moe, PhD, was an Executive in Residence at Duke's Fuqua School of Business and, since 2012, an adjunct faculty member at DGHI. Dr. Moe and two Duke colleagues, David Ridley and Henry Grabowski, are widely known for their 2006 article, "Developing Drugs for Developing Countries," published in Health Affairs, which recommended a prize -- a priority review voucher (PRV) -- to reward new therapeutics and diagnostics for neglected diseases. The 2007 FDA Amendments Act made the PRV into law.
In addition to a continuing interest in incentives for neglected diseases, Dr. Moe researches health care delivery innovation and health care financing and payment reforms in low and middle income health care markets. He is also collaborating with ethicists, public agencies and private firms regarding the ethical challenges when patients demand expanded access to new therapeutics and public private partnerships are created to accelerate the discovery of innovative therapeutics.